This Article Full Text Full Text (PDF) All Versions of this Article: bjo.2007.123513v1 92/3/351    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kreutzer, T C Articles by Priglinger, S Search for Related Content PubMed PubMed Citation Articles by Kreutzer, T C Articles by Priglinger, S Topic Collections Relevant Article

Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion

¹ Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany
² Department of Ophthalmology, Medical University, Innsbruck, Austria

Correspondence to:
Dr S G Priglinger, Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Mathildenstr 8, 80336 Munich, Germany; siegfried.priglinger{at}med.uni-muenchen.de

Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion.

Methods: A prospective, non-comparative, consecutive, interventional case series of 34 patients. Patients received repeated intravitreal injections of 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and retinal thickness (optical coherence tomography measurements) in a follow-up period of 6 months.

Results: Patients presented at a mean age of 69 years (range 44–86). Mean duration of symptoms was 40 weeks (range 1–300). Mean (SD) VA at baseline was 0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = 0.009). Mean number of letters on the ETDRS chart at baseline was 45.3 (19.0), improving to 60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal thickness at baseline was 474 (120) µm, declining to 316 (41) µm at 6 months.

Conclusion: Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion.

Competing interests: None declared.

Relevant Article

At a glance

Harminder S Dua and Arun D Singh, Editors-in
Br. J. Ophthalmol. 2008 92: 301. [Extract] [Full Text] [PDF]